Cargando…

Influence of Genetics on the Response to Omalizumab in Patients with Severe Uncontrolled Asthma with an Allergic Phenotype

Omalizumab is a monoclonal antibody indicated for the treatment of severe uncontrolled asthma with an allergic phenotype. Its effectiveness could be influenced by clinical variables and single nucleotide polymorphisms (SNPs) in one or more of the genes involved in the mechanism of action and process...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rojo-Tolosa, Susana, Sánchez-Martínez, José Antonio, Pineda-Lancheros, Laura Elena, Gálvez-Navas, José María, González-Gutiérrez, María Victoria, Jiménez-Gálvez, Gonzalo, Pérez-Ramírez, Cristina, Morales-García, Concepción, Jiménez-Morales, Alberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10139019/ https://www.ncbi.nlm.nih.gov/pubmed/37108192 http://dx.doi.org/10.3390/ijms24087029

Ejemplares similares

Impact of Omalizumab in Patients with Severe Uncontrolled Asthma and Possible Predictive Biomarkers of Response: A Real-Life Study
por: Rojo-Tolosa, Susana, et al.
Publicado: (2023)

Impact of Anti-IL5 Therapies on Patients with Severe Uncontrolled Asthma and Possible Predictive Biomarkers of Response: A Real-Life Study
por: Rojo-Tolosa, Susana, et al.
Publicado: (2023)

Association between Single Nucleotide Polymorphisms Related to Vitamin D Metabolism and the Risk of Developing Asthma
por: Rojo-Tolosa, Susana, et al.
Publicado: (2023)

Vitamin D-Related Single Nucleotide Polymorphisms as Risk Biomarker of Cardiovascular Disease
por: González Rojo, Paula, et al.
Publicado: (2022)

Effect of Single Nucleotide Polymorphisms in the Vitamin D Metabolic Pathway on Susceptibility to Non-Small-Cell Lung Cancer
por: Pineda Lancheros, Laura Elena, et al.
Publicado: (2022)

Single Nucleotide Polymorphisms in the Vitamin D Metabolic Pathway and Their Relationship with High Blood Pressure Risk
por: Rojo-Tolosa, Susana, et al.
Publicado: (2023)

Polymorphisms in VDR, CYP27B1, CYP2R1, GC and CYP24A1 Genes as Biomarkers of Survival in Non-Small Cell Lung Cancer: A Systematic Review
por: Pineda-Lancheros, Laura Elena, et al.
Publicado: (2023)

Cost-effectiveness of tiotropium versus omalizumab for uncontrolled allergic asthma in US
por: Zafari, Zafar, et al.
Publicado: (2018)

Single Nucleotide Polymorphisms in the Vitamin D Metabolic Pathway as Survival Biomarkers in Colorectal Cancer
por: Pérez-Durán, Carmen, et al.
Publicado: (2023)

Effectiveness of omalizumab in children and adolescents with uncontrolled allergic asthma: a case series from Poland
por: Sztafińska, Anna, et al.
Publicado: (2021)

Impact of Genetic Polymorphisms on the Metabolic Pathway of Vitamin D and Survival in Non-Small Cell Lung Cancer
por: Pineda Lancheros, Laura Elena, et al.
Publicado: (2021)

Real-world effectiveness and safety of omalizumab in patients with uncontrolled severe allergic asthma from the Czech Republic
por: Kirchnerová, Olga Růžičková, et al.
Publicado: (2018)

Omalizumab for Severe Asthma: Beyond Allergic Asthma
por: Loureiro, C. C., et al.
Publicado: (2018)

Influence of the diagnosis chronic rhinosinusitis on asthma response to omalizumab in severe, uncontrolled asthmatics
por: Sintobin, Ina, et al.
Publicado: (2015)

Omalizumab in patients with severe uncontrolled asthma: well-defined eligibility criteria to promote asthma control
por: de Carvalho-Pinto, Regina Maria, et al.
Publicado: (2017)

Real-world effectiveness of omalizumab for severe allergic asthma treatment in Colombia
por: Torres-Duque, Carlos A., et al.
Publicado: (2022)

Long-term efficacy and safety of omalizumab in patients with persistent uncontrolled allergic asthma: a systematic review and meta-analysis
por: Lai, Tianwen, et al.
Publicado: (2015)

The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma
por: Chapman, Kenneth R., et al.
Publicado: (2019)

Omalizumab as add-on therapy in patients with asthma and allergic bronchopulmonary aspergillosis
por: da Cunha, Fernanda Sales, et al.
Publicado: (2018)

4-month omalizumab efficacy outcomes for severe allergic asthma: the Dutch National Omalizumab in Asthma Registry
por: Snelder, S. M., et al.
Publicado: (2017)

Corrigendum: Long-term efficacy and safety of omalizumab in patients with persistent uncontrolled allergic asthma: a systematic review and meta-analysis
por: Lai, Tianwen, et al.
Publicado: (2015)

Clinical and economic consequences of switching from omalizumab to mepolizumab in uncontrolled severe eosinophilic asthma
por: Carpagnano, Giovanna Elisiana, et al.
Publicado: (2021)

Omalizumab: the evidence for its place in the treatment of allergic asthma
por: McNicholl, Diarmuid M., et al.
Publicado: (2008)

Omalizumab: An Optimal Choice for Patients with Severe Allergic Asthma
por: Kotoulas, Serafeim Chrysovalantis, et al.
Publicado: (2022)

Omalizumab and IgE in the Control of Severe Allergic Asthma
por: Gon, Yasuhiro, et al.
Publicado: (2022)

The dynamics of the manifestations of atopic dermatitis in severe persistent uncontrolled asthma children with omalizumab therapy
por: Vishneva, Elena, et al.
Publicado: (2015)

Omalizumab in the management of patients with allergic (IgE-mediated) asthma
por: Sandström, Thomas
Publicado: (2009)

270 Clinical Experience in Allergic Asthma Patients: Omalizumab with Immunotherapy
por: Yalcin, Arzu Didem, et al.
Publicado: (2012)

Omalizumab for severe allergic asthma: a life changing drug?
por: Mesonjesi, Eris, et al.
Publicado: (2015)

Sex, Allergic Diseases and Omalizumab
por: Sirufo, Maria Maddalena, et al.
Publicado: (2022)

The “real-world” effectiveness and safety of omalizumab in patients with uncontrolled persistent allergic asthma in Slovakia: a subgroup analysis of the eXpeRience study
por: Siracká, Simona, et al.
Publicado: (2022)

Real-life Effectiveness of Omalizumab in Patients with Severe Allergic Asthma: RELIEF Study
por: Al Ahmad, Mona, et al.
Publicado: (2022)

Omalizumab in Children with Severe Allergic Asthma: The Italian Real-Life Experience
por: Licari, Amelia, et al.
Publicado: (2017)

Omalizumab and unmet needs in severe asthma and allergic comorbidities in Japanese children
por: Nishima, Sankei, et al.
Publicado: (2019)

Omalizumab for the treatment of severe allergic asthma in children: A tale of two
por: Brannick, Sinéad, et al.
Publicado: (2022)

Specific IgE Response and Omalizumab Responsiveness in Severe Allergic Asthma
por: Tajiri, Tomoko, et al.
Publicado: (2023)

Selectivity and Specificity Are the Keys to Cost-Effective Use of Omalizumab for Allergic Asthma
por: Curtiss, Frederic R.
Publicado: (2005)

Successful treatment of severe allergic asthma with omalizumab in a girl with DiGeorge syndrome
por: JESENAK, MILOS, et al.
Publicado: (2020)

155 Omalizumab Improves Asthma but not Nasal Symptoms in Japanese Patients With Severe Allergic Asthma and Rhinitis
por: Nishihara, Fuyumi, et al.
Publicado: (2012)

279 Near-Fatal Asthma Treated with Omalizumab
por: Contreras Contreras, Elvia Angelica, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_bkdsi1qp94ne4ah01tf3u986h1